sensei(US:SNSE)2026-03-30 11:35Financial Results Announcement - Sensei Biotherapeutics, Inc. announced its financial results for the full year ended December 31, 2025, on March 30, 2026[4]. - The press release detailing the financial results is attached as Exhibit 99.1[4]. - The report does not include specific financial metrics or performance indicators, as the detailed financial results are in the attached press release[4]. Regulatory Compliance - The company is classified as an emerging growth company under the Securities Act of 1933[3]. - The report was filed under the Securities Exchange Act of 1934, indicating compliance with regulatory requirements[5]. - The filing does not incorporate any information by reference into other filings under the Exchange Act or the Securities Act[5]. - The company has not elected to use the extended transition period for complying with new financial accounting standards[3]. Company Information - The company's principal executive offices are located in Rockville, MD[1]. - The common stock of Sensei Biotherapeutics is traded on The Nasdaq Stock Market under the symbol SNSE[2]. - The report was signed by Christopher W. Gerry, President and General Counsel, on March 30, 2026[10].